Bayer HealthCare and Nektar Therapeutics have agreed to develop and commercialize NKTR-061 (inhaled amikacin). NKTR-061 is under development for adjunctive treatment of Gram-negative pneumonias that often lead to significant morbidity and mortality. Nektar’s proprietary pulmonary technology would be employed to deliver a specially-formulated amikacin, an aminoglycoside antibiotic, for inhalation deep into the lung. As part of this agreement, Nektar will receive milestone payments of up...